Scarica l'app Stockscreener
7.84
7.25%
0.53
Dopo l'orario di chiusura:
7.44
-0.40
-5.10%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ALGS Giù?
Forum
Previsione
Aligos Therapeutics Inc Borsa (ALGS) Ultime notizie
Aligos Therapeutics (ALGS) Welcomes New VP of Chemistry Manufacturing Controls | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing - Bluefield Daily Telegraph
Aligos Therapeutics Strengthens Drug Development Team: Former Kezar Executive to Drive Phase 2 Trial Progress - Stock Titan
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Lis - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule - MarketScreener
Aligos Therapeutics (ALGS) Issues Stock Options to New Employees | ALGS Stock News - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Aligos Therapeutics Awards Major Stock Options Package: New Employees Get 26,000 Shares Under Nasdaq Rule - Stock Titan
(ALGS) Long Term Investment Analysis - news.stocktradersdaily.com
5,157 Shares in Aligos Therapeutics, Inc. (NASDAQ:ALGS) Bought by Northern Trust Corp - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Sees Large Decline in Short Interest - Defense World
Clinical Stage Liver Disease Biotech Aligos Set for Major Jefferies Conference Presentation - Stock Titan
How the (ALGS) price action is used to our Advantage - news.stocktradersdaily.com
Financial Comparison: Entera Bio (NASDAQ:ENTX) versus Aligos Therapeutics (NASDAQ:ALGS) - Defense World
Aligos Therapeutics (ALGS) Appoints New Head of Legal | ALGS Stock News - GuruFocus
Aligos Therapeutics Appoints Laura Kavanaugh as Vice President, Head of Legal - The Manila Times
Former Genentech and Codexis Legal Leader Takes Top Legal Role at Liver Disease Biotech Aligos - Stock Titan
Aligos Therapeutics Issues 26,000-Share Inducement Grant To New Employee - Nasdaq
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Gran - GuruFocus
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ALGS Stock News - GuruFocus
Aligos Therapeutics (ALGS) Awards New Employee Stock Option Grant | ALGS Stock News - GuruFocus
Aligos Therapeutics Expands Liver Disease Team with Strategic Hire, Awards 26,000 Share Options - Stock Titan
Aligos Therapeutics First Quarter 2025 Earnings: Revenues Miss Expectations - Yahoo Finance
Here's Why We're A Bit Worried About Aligos Therapeutics' (NASDAQ:ALGS) Cash Burn Situation - simplywall.st
Aligos reports promising HBV treatment data at EASL Congress - Investing.com
Aligos Therapeutics (ALGS) Showcases Promising HBV Treatment Results at EASL Congress 2025 | ALGS Stock News - GuruFocus
Aligos reports promising HBV treatment data at EASL Congress By Investing.com - Investing.com Nigeria
Aligos Therapeutics Presents Positive Data at the EASL Congress 2025 - The Manila Times
Aligos Therapeutics, Inc. (ALGS) Reports Q1 Loss, Misses Revenue Estimates - MSN
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results - ADVFN
Aligos Therapeutics Reports Strong Q1 2025 Progress - TipRanks
Aligos Therapeutics (ALGS) Reports Lower Q1 Revenue, Advances Ke - GuruFocus
Aligos Therapeutics Inc Reports Q1 2025 EPS of $5.12, Surpassing Estimates; Revenue Slightly Misses at $0.31 Million - GuruFocus
ALIGOS THERAPEUTICS Earnings Results: $ALGS Reports Quarterly Earnings - Nasdaq
Aligos Therapeutics, Inc. SEC 10-Q Report - TradingView
Aligos Reports Surprise $43M Profit: Breakthrough HBV Drug Shows 100% Response Rate at 96 Weeks - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Aligos Therapeutics (ALGS) Projected to Post Earnings on Tuesday - Defense World
Aligos Therapeutics, Inc. (NASDAQ:ALGS) Stake Lessened by Renaissance Technologies LLC - Defense World
Aligos Therapeutics Inc expected to post a loss of $2.80 a shareEarnings Preview - TradingView
Aligos Therapeutics (ALGS) Gains Buy Rating with Promising Outlo - GuruFocus
Aligos Therapeutics (ALGS) Coverage Initiated with Positive Outl - GuruFocus
Wells Fargo & Company MN Invests $869,000 in Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Geode Capital Management LLC Buys 3,197 Shares of Aligos Therapeutics, Inc. (NASDAQ:ALGS) - Defense World
Aligos Therapeutics to Announce 1st Quarter 2025 Financial Results on May 6, 2025 - The Manila Times
Aligos Therapeutics Q1 2025 Earnings: Clinical Stage Biotech Reports Pre-Market May 6Key Focus Areas - Stock Titan
Aligos Therapeutics Announces Eight Abstracts Accepted for Presentation at the EASL Congress 2025 - The Manila Times
When the Price of (ALGS) Talks, People Listen - news.stocktradersdaily.com
ALGS stock touches 52-week low at $4.21 amid market challenges By Investing.com - Investing.com South Africa
ALGS stock touches 52-week low at $4.21 amid market challenges - Investing.com India
How Much Upside is Left in Aligos Therapeutics (ALGS)? Wall Street Analysts Think 648.14% - MSN
(ALGS) Investment Analysis - news.stocktradersdaily.com
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):